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ABSTRACT
Background: Mutations and deletions of the homeobox
transcription factor gene SHOX are known to cause short
stature. The authors have analysed SHOX enhancer
regions in a large cohort of short stature patients to study
the importance of regulatory regions in developmentally
relevant genes like SHOX.
Methods: The authors tested for the presence of copy
number variations in the pseudoautosomal region of the
sex chromosomes in 735 individuals with idiopathic short
stature and compared the results to 58 cases with Leri–
Weill syndrome and 100 normal height controls, using
fluorescence in situ hybridisation (FISH), single nucleotide
polymorphism (SNP), microsatellites, and multiplex ligand
dependent probe amplification (MLPA) analysis.
Results: A total of 31/735 (4.2%) microdeletions were
identified in the pseudoautosomal region in patients with
idiopathic short stature; eight of these microdeletions (8/
31; 26%) involved only enhancer sequences residing a
considerable distance away from the gene. In 58 Leri–
Weill syndrome patients, a total of 29 microdeletions
were identified; almost half of these (13/29; 45%) involve
enhancer sequences and leave the SHOX gene intact.
These deletions were absent in 100 control persons.
Conclusion: The authors conclude that enhancer
deletions in the SHOX gene region are a relatively frequent
cause of growth failure in patients with idiopathic short
stature and Leri–Weill syndrome. The data highlights the
growing recognition that regulatory sequences are of
crucial importance in the genome when diagnosing and
understanding the aetiology of disease.
Short stature is a developmental, multifactorial
condition with a strong genetic component. Three
per cent of the population are defined as being
short. Short stature can have many different
causes, a multitude of which are genetic. Several
large scale genome wide association studies have
recently determined variants that affect suscept-
ibility to disease and identified a total of 54
validated single nucleotide polymorphism (SNP)
variants with an influence on height.
1–3 However,
in total these large scale studies only pinpointed
candidate genes of relatively minor effect within
each locus, explaining only a small proportion of
the phenotypic variance in the normal population,
and thus accounting together for little more than
5% of our height (0.4 cm per ‘‘increasing’’ allele).
Although mutations in several genes have been
reported that cause pronounced short or tall
stature with a drastic effect on height (10–30 cm
per ‘‘mutant’’ allele), this normally accounts for
only a very small proportion of patients with short
stature. So we are left with the fact that for the
vast majority of short individuals with a height
below 22 standard deviations scores (SDS), no
causing defects are known, clinically termed as
‘‘idiopathic’’ short stature.
4
One of the more prevalent causes of short
stature was shown to derive from a defect in a
developmental gene on the X chromosome, SHOX
(short stature homeobox gene; MIM 312865).
Defects in the coding region of SHOX have been
demonstrated in individuals with different short
stature syndromes including Leri–Weill, Langer and
Turner syndrome (MIM 127300),
5–8 but mutations
are also found in patients with idiopathic short
stature (ISS) (MIM 300582).
9
Regulatory elements residing either 59 or 39 of a
gene can be sites of mutations in genetic disease
and interfere with the normal expression of a gene.
Some of these elements—defined as enhancers or
repressors—can lie a considerable distance away
from the coding portion of a gene.
10 Enhancer
elements can act upstream and downstream of a
gene and function only in certain cell types. In
concert with transcription factors that bind to
these enhancer sequences, they play a role in
achieving the appropriate level of gene expression.
Defects in enhancer sequences have as yet only
rarely been identified, and like promoter muta-
tions, are considered to play only a relatively minor
role in disease.
Comparative genomic analysis has previously
identified evolutionarily conserved non-coding
DNA elements, termed CNE, several hundred
kilobases downstream of the SHOX gene in
patients with Leri–Weill syndrome (LWS).
11–14
Three of these elements have subsequently been
shown to act as enhancers in the chicken limb bud
and five elements as enhancers in the neural tube.
15
To establish the frequency and significance of long
range regulatory elements also in individuals with
idiopathic short stature (ISS), we have analysed the
DNA of 735 patients with ISS and compared these
results to 58 patients with a clinical manifestation
of LWS and 100 controls.
SUBJECTS AND METHODS
The study was conducted in accordance with the
principles of the Declaration of Helsinki/Good
Clinical Practice and was approved by the ethics
committees of the participating institutions.
Investigators obtained written informed consent
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conducting study related procedures.
Study subjects
We studied 740 unrelated pre-pubertal children with ISS from
14 countries: Belgium (n=61), Canada (n=39), Croatia
(n=34), Czech Republic (n=87), France (n=60), Germany
(n=144), Hungary (n=29), India (n=7), Netherlands (n=2),
Poland (n=49), Russia (n=6), Spain (n=107), Turkey
(n=61), and USA (n=54). Inclusion criteria were: chronolo-
gical age >3 years and pre-pubertal (males: genital stage Tanner
1 and testes (2 ml; females: breast stage Tanner 1); height
(3rd centile of the local reference range or height (10th centile
with height velocity (25th centile; bone age (10 years for
boys and (8 years for girls; no growth hormone (GH)
deficiency or GH resistance; no chronic disease; and no known
growth influencing medications.
Our study also included 67 patients with LWS from eight
different European countries: Germany (n=37), Austria
(n=1), Croatia (n=4), France (n=10), Italy (n=2),
Netherlands (n=8), Spain (n=4), and Sweden (n=1). The
control cohort consisted of 100 individuals of European origin
with normal stature. We used a combination of DNA
sequencing, microsatellite analysis, fluorescence in situ hybridi-
sation (FISH), and multiplex ligand dependent probe amplifica-
tion (MLPA),
16 to search for copy number variations in the
proximity of SHOX in the pseudoautosomal region (PAR1).
Details are given in the supplemental appendix.
RESULTS
The main focus of this study was to find out about the
frequency of enhancer deletions in a large cohort of patients
with ISS and compare the results to patients with LWS and
control individuals. Patients that presented (point) mutations
within the SHOX gene were excluded from the deletion analysis
(five patients with ISS, nine patients with LWS), leaving
altogether 735 patients with ISS, 58 patients with LWS, and 100
controls for the enhancer deletion analysis.
To screen for enhancer deletions downstream of the SHOX
gene, we carried out MLPA on 201 of the 735 ISS patients. These
201 patients were selected as they showed homozygosity with
at least one of the microsatellite markers (DXYS10085,
DXYS10087, and DXYS10096), in addition to the limb specific
enhancer CNE9, all residing at a distance of 150–250 kb from
the SHOX gene (fig 1).
We have also screened the 735 ISS patients for homozygosity
of two markers in direct vicinity of the SHOX gene (DXYS201
and CAII),
14 to pinpoint SHOX containing deletions. In all
individuals where all two markers were homozygous, FISH
analysis was carried out, and in 18 individuals a deletion of the
SHOX gene was demonstrated by FISH. In these 18 individuals,
MLPA was also carried out additionally as a further confirma-
tion for the SHOX containing deletions. MLPA analysis was also
carried out in DNA of 58 LWS patients who had been previously
tested for the presence or absence of the SHOX gene and in
DNA of 100 control individuals.
In total, MLPA analysis demonstrated a deletion in the
pseudoautosomal region of 33/201 tested ISS patients, with
peaks at a ratio ,0.5 as compared to normal controls (fig 2).
Deletion sizes ranged between 52 kb and several megabases of
DNA and no duplications were detected. Twenty-three of the
33 microdeletions included the SHOX gene. A comparison of the
results to the control cohort showed that two of the deletions
(no. 27 and 28; see fig 2) represent polymorphisms as they were
also detected in two control individuals (fig 2). Among the 31
remaining microdeletions of the PAR region, eight ISS patients
presented deletions including only the enhancer sequences,
CNE7, CNE8 and/or CNE9 (no. 24–26, 29–33; fig 2). Three of
Figure 1 Schematic representation of
the PAR1 region showing the position of
evolutionarily conserved non-coding DNA
elements (CNEs), microsatellites and
cosmids that were used for deletion
mapping.
15 The SHOX gene is indicated in
red and resides between 505.1 and
540.1 kb from the telomere (NCBI build
125, March 2006). The CNEs and
microsatellites used for deletion mapping
are shown above the scale bar. CNEs are
indicated in green; CNE4, CNE5 and CNE9
with a star symbol have shown enhancer
activity in the developing chicken limb
bud.
15 CNE3, CNE4, CNE5, CNE7 and
CNE9 have previously shown enhancer
activity in the chicken neural tube.
15
Microsatellites are indicated in blue. The
SHOX exons and the cosmids contig used
for deletion mapping are shown below the
scale bar. Cosmid 34F05
(LLN0YCO39M34F05) includes the SHOX
gene; Cosmid 51D11
(LLN0YCO3’M’51D11) includes CNE6,
CNE7 and markers DXYS10085; Cosmid
61E05 (LLN0YCO3’M’61E05) includes
CNE8 and markers DXYS10087 and
DXYS10096; Cosmid 10D05
(LLN0YCO3’M’10D05) includes CNE9.
TEL, telomere; CEN, centromere.
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only the enhancer intervals CNE7 and CNE8, and in proband 32
only the CNE8 interval was deleted (CNEs as defined by
Sabherwal et al
15).
MLPAanalysisalsodemonstratedaheterozygousdeletioninthe
PAR region in 30/58 LWS patients, showing all the peaks at a ratio
,0.5 as compared to normal controls. Among the 30 microdele-
tions, 16 deletions encompassed the SHOX gene, whereas 14
deletions were located downstream of the SHOX gene. The
smallest deletion (no. 49, fig 2) included exons 4–5 of the SHOX
gene (10 kb) and was only detectable by MLPA. A comparison
with the controls demonstrated that the deletion in one of the
patients (no. 50) represents a polymorphism. Among the 29
microdeletions of the PAR1 region in LWS patients, one patient
(no. 62) included only the enhancer interval CNE7 and CNE8.
Altogether, we identified 63 persons with copy number
variations in the PAR region by screening 793 patients with
short stature (735 with ISS and 58 with LWS). Sixty of these
deletions were absent in a series of 100 control persons, while
three were also found in the control group and had to be judged
as normal variants (no. 27, 28, 50). To confirm these results
with an independent method, we carried out FISH on
chromosomes of several patients with small deletions, where
metaphase spreads were available (no. 24–26, 29–33, 62). In all
Figure 2 Mapping of 63 PAR deletions
in patients with idiopathic short stature
(ISS) and Leri–Weill syndrome (LWS)
using the SALSA P018C and P018D-1
SHOX MLPA kit. Maximum deletion sizes
are according to Ensemble Genome
Browser coordinates (in kb) and are given
on the right side. Blackened areas
indicate the presence of two copies of the
MLPA probe; white areas indicate the
deletion of one allele; green areas indicate
the presence of more than two copies of
the MLPA probe; grey areas indicate the
common minimal deletion interval in
patients, and solidus areas indicate that
the analyzed marker was non-informative.
The ISS 24-33 and LWS 50-63 patients
present cases with an intact SHOX region
and downstream deletions. In the control
population, two deletions of the locus at
685 Xptel, a duplication of locus at 818
Xptel, as well as two duplications of the
ASMT gene at 1711 Xptel were found.
Note also that in one patient (no.9) a
deletion of the STS gene was identified.
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idiopathic short stature. The CNE9-
containing cosmid 10D05
(LLN0YCO3’M’10D05) was used as a
probe for FISH analysis. (A) Metaphase
chromosomes from a female control with
FISH signals on both X chromosomes. (B)
Metaphase chromosomes from a female
patient (no. 24) with a deletion on one of
the chromosomes (arrows). (C)
Metaphase from a male control with FISH
signals on both X and Y chromosomes.
(D) Metaphase from a male patient (no.
33) with a deletion on the Y chromosome
(arrows) but not on the X chromosome. A
reference probe residing on the long arm
of the X-chromosome (cosmid P9) and a
Y centromeric probe (DYZ3) were used as
controls. The green signals indicate
cosmids 10D05 and P9 and hybridised to
opposite ends of the X chromosome; the
red signal indicates probe DYZ3.
Figure 4 Summary of the spectrum of
different SHOX mutations in patients with
idiopathic short stature (ISS) and Leri–
Weill syndrome (LWS). From all studied
735 unrelated patients with ISS, 31 are
caused by SHOX-related deletions. Eight
presented deletions proximal to SHOX
(black) and 23 presented a SHOX gene
deletion (hatched). A further five patients
with ISS presented an intragenic mutation
(white; 4 missense, 1 frameshift mutation;
data not shown), which were initially
excluded from the deletion study (total
number of patients with ISS: 740). In 67
unrelated LWS, 38 are caused by SHOX-
related defects: 13 presented a deletion
downstream of SHOX(black), 16presented
a SHOX gene deletion (hatched) and nine
presented an intragenic mutation (white; 5
missense, 3 nonsense, 1 frameshift
mutation).Theninepatientswithintragenic
mutations were initially excluded from the
deletion study. In total, 4.9% of patients
with ISS and 56.7% of patients with LWS
are caused by point mutations or deletions
of SHOX or its regulatory regions.
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cosmids 51D11, 61E05 and 10D05 with a map location between
670–780 kb from the telomere (fig 3).
To further correlate the significance of one or more of the
enhancer CNE elements in SHOX downstream deletions, a
detailed analysis of the deletion boundaries was carried out in
seven ISS cases (no. 27–33) and one LWS case (no. 62) by SNP
and microsatellite analysis (supplemental fig). The smallest
deletion was confined to (2 kb in proband 27 and 28 and
represents a polymorphism; proband 33 had a deletion of
(80 kb. In three individuals with ISS and one individual with
LWS, a deletion interval smaller than 60 kb was detected that
included the CNE7 and CNE8 enhancer interval. The deletion in
ISS proband 32 was the smallest detectable functional variant in
this series and included only the CNE8 interval.
DISCUSSION
This study was performed to establish a comprehensive view of
copy number variations in the pseudoautosomal region of the
human sex chromosomes in 735 patients with idiopathic short
stature. The pseudoautosomal region represents a block of
sequence identity shared between the X and Y chromosomes,
flanked by the telomere. It is characterised by an elevated CG
content, abundant Alu repeats, and one of the highest
recombination rates in the human genome.
17 Deletions in the
pseudoautosomal region were identified in 33 of the 735
screened ISS patients (4.5%); 31 of these were not found in
the screened controls. Deletions in the PAR1 region were also
identified in 30 of the 58 screened LWS cases and in three of the
analysed controls. As we were interested in the level and
significance of enhancer deletions in patients with idiopathic
short stature with regard to the overall frequency of detected
mutations/deletions, the incidence of enhancer deletions of 22%
was an unexpected finding, while this proportion was even
higher at 34% in patients with LWS. Figure 4 gives a summary
of all the SHOX gene deletions, the intragenic mutations and
downstream enhancer deletions in the analysed patients with
ISS and LWS. It is very likely that these high incidences are still
an underestimate, as we cannot rule out the possibility that
some cases have been overlooked due to point mutations in
enhancer sequences or deletions in other parts of this region.
Do cis-regulatory mutations in ISS or LWS make a
qualitatively different contribution to disease? LWS is clinically
defined by a shortened middle portion of the limb (mesomelia)
leading to short stature and an abnormal alignment of the
radius and ulna at the wrist. The Madelung deformity typically
develops at puberty and females are generally more severely
affected than males. Other clinical features include a high
muscle mass and high body mass index.
14 18 19 As cis-regulatory
deletions in our analysis occur more frequently in patients with
LWS compared to ISS, it is possible that enhancer deletions may
lead to more pronounced phenotypes, as exemplified in the
more striking phenotype of LWS.
The deletion of the limb specific enhancer CNE9 has been
previously shown to be an important cis-controlling element in
SHOX haploinsufficiency.
11–13 15 This study confirms that CNE9
probably represents the most important enhancer in the
proximal SHOX region, but also has revealed that CNE8
together with CNE7, and also the deletion of the CNE8 interval
alone, can be identified in patients with short stature as well as
skeletal defects (no. 29–32, 62; supplemental fig). Alternatively,
it also cannot be totally ruled out that the deletion of the CNE7
and CNE8 intervals may have only a minor effect, as this
interval was absent in the sequence data of one recently
sequenced individual; however, pedigree data were not available
and SNP and microsatellite analysis, MLPA and FISH was not
carried out.
20 It is also possible that this part of the sequence is
still inaccurate or incomplete. We also know that the phenotype
in patients can be very variable (intra- and interfamiliar) and
that there are individuals with SHOX deficiency and normal
stature.
12 14
Long range transcriptional control by enhancer sequences
have been identified mostly through the analysis of patients
with genetic malformations and found to reside up to hundreds
of kilobases away from the genes they control.
10 Three examples
of long range control in limb development include enhancers in
the vicinity of the mammalian Hoxd cluster
21 and the Sox9 gene,
defects in which cause campomelic dysplasia, a dominant
skeletal malformation syndrome often associated with XY sex
reversal, or Pierre Robin sequence, an important subgroup of
cleft palate.
22–24 Chromosome rearrangements which separate
the genes from their conserved non-coding DNA elements have
only been reported in a small minority of cases. The PAX6 and
SHH position effect cases are further good examples of the
separation of cis-regulatory elements.
10 Given the findings on
enhancer significance on key regulatory master genes in the
literature, the high level of enhancer deletions in the SHOX gene
is to our knowledge unprecedented in the human genome.
The conserved non-coding elements in the vicinity of the
SHOX gene are embedded in a region with characteristics of a
gene desert. Deletions encompassing more proximal or more
distal pseudoautosomal genes have been detected in a number
of patients in our study, but this does not lead to obvious
phenotypic consequences. The same holds true for a duplication
of the ASMT gene which was found in two normal controls. An
important diagnostic issue has, however, been raised, related to
the observation that five female probands carry deletions
extending into the X-specific region of the X chromosome.
While these females only present short stature, their male babies
could also suffer from mental retardation, chondrodysplasia
punctata, ichthyosis, and Kallmann syndrome,
25 depending on
their exact deletion size and which X chromosomal genes are
missing. For these individuals, prenatal diagnosis might
represent an option.
In summary, we have applied DNA sequencing, microsatellite,
FISH and MLPA analysis to detect DNA rearrangements in a
large cohort of patients with idiopathic short stature of different
ethnic origin. We have provided strong evidence that cis-
regulatory deletions can contribute to the patient’s condition to
an unexpectedly high degree. These data also re-emphasise that
regulatory input can be crucial for developmental genes, most
notably genes with a dynamic expression pattern. Lastly, our
findings also help to optimise diagnostic options for individuals
with SHOX haploinsufficiency and thus may have immediate
value for patients with idiopathic short stature.
Acknowledgements: We thank Eva Decker, Claudia Durand and Claire Bacon for
reading of this manuscript.
Funding: This work was supported by the Deutsche Forschungsgemeinschaft and the
Land Baden-Wu ¨rttemberg. Jianjun Chen was supported by a grant of the postdoctoral
fellowship program of the Faculty of Medicine, Heidelberg.
Competing interests: GW, DS and JD are (or were) employees of the Bioscientia
Institute of Medical Genetics, WB is an employee of Eli Lilly and company. GRi sa
patent owner and has been reimbursed by Eli Lilly for attending and speakinga t
several conferences. JC, ZZ, RR, and BW have no competing interests.
Patient consent: Obtained.
Provenance and peer review: Not commissioned; externally peer reviewed.
Original article
838 J Med Genet 2009;46:834–839. doi:10.1136/jmg.2009.067785REFERENCES
1. Gudbjartsson DF, Walters GB, Thorleifsson G, Stefansson H, Halldorsson BV,
Zusmanovich P, Sulem P, Thorlacius S, Gylfason A, Steinberg S, HelgadottirA ,
Ingason A, Steinthorsdottir V, Olafsdottir EJ, Olafsdottir GH, Jonsson T, Borch-
Johnsen K, Hansen T, Andersen G, Jorgensen T, Pedersen O, Aben KK, Witjes JA,
Swinkels DW, den Heijer M, Franke B, Verbeek AL, Becker DM, Yanek LR, Becker LC,
Tryggvadottir L, Rafnar T, Gulcher J, Kiemeney LA, Kong A, Thorsteinsdottir U,
Stefansson K. Many sequence variants affecting diversity of adult human height. Nat
Genet 2008;40:609–15.
2. Lettre G, Jackson AU, Gieger C, Schumacher FR, Berndt SI, Sanna S, Eyheramendy
S, Voight BF, Butler JL, Guiducci C, Illig T, Hackett R, Heid IM, Jacobs KB, Lyssenko V,
Uda M, Diabetes Genetics Initiative, FUSION, KORA, Prostate, Lung Colorectal and
Ovarian Cancer Screening Trial, Nurses’ Health Study, SardiNIA, Boehnke M, Chanock
SJ, Groop LC, Hu FB, Isomaa B, Kraft P, Peltonen L, Salomaa V, Schlessinger D,
Hunter DJ, Hayes RB, Abecasis GR, Wichmann HE, Mohlke KL, Hirschhorn JN.
Identification of ten loci associated with height highlights new biological pathways in
human growth. Nat Genet 2008;40:584–91.
3. Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, Mangino M, Freathy
RM, Perry JR, Stevens S, Hall AS, Samani NJ, Shields B, Prokopenko I, FarrallM ,
Dominiczak A, Diabetes Genetics Initiative, Wellcome Trust Case Control Consortium,
Johnson T, Bergmann S, Beckmann JS, Vollenweider P, Waterworth DM, Mooser V,
Palmer CN, Morris AD, Ouwehand WH, Cambridge GEM Consortium, Zhao JH, Li S,
Loos RJ, Barroso I, Deloukas P, Sandhu MS, Wheeler E, Soranzo N, Inouye M,
Wareham NJ, Caulfield M, Munroe PB, Hattersley AT, McCarthy MI, Frayling TM.
Genome-wide association analysis identifies 20 loci that influence adult height. Nat
Genet 2008;40:575–83.
4. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage
MO, Wit JM, 2007 ISS Consensus Workshop participants. Consensus statemento n
the diagnosis and treatment of children with idiopathic short stature. J Clin Endocrinol
Metab 2008;93:4210–7.
5. Ellison JW, Wardak Z, Young MF, Gehron Robey P, Laig-Webster M, Chiong W.
PHOG, a candidate gene for involvement in the short stature of Turner syndrome.
Hum Mol Genet 1997;6:1341–7.
6. Belin V, Cusin V, Viot G, Girlich D, Toutain A, Moncla A, Vekemans M, Le Merrer M,
Munnich A, Cormier-Daire V. SHOX mutations in dyschondrosteosis (Leri-Weill
syndrome). Nat Genet 1998;19:67–9.
7. Shears DJ, Vassal HJ, Goodman FR, Palmer RW, Reardon W, Superti-Furga A,
Scambler PJ, Winter RM. Mutation and deletion of the pseudoautosomal gene SHOX
cause Leri-Weill dyschondrosteosis. Nat Genet 1998;19:70–3.
8. Kosho T, Muroya K, Nagai T, Fujimoto M, Yokoya S, Sakamoto H, Hirano T, Terasaki
H, Ohashi H, Nishimura G, Sato S, Matsuo N, Ogata T. Skeletal features and growth
patterns in 14 patients with haploinsufficiency of SHOX: implications for the
development of Turner syndrome. J Clin Endocrinol Metab 1999;84:4613–21.
9. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch
S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A,
Ogata T, Rappold GA. Pseudoautosomal deletions encompassing a novel homeobox
gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet
1997;16:54–63.
10. Kleinjan DA, van Heyningen V. Long-range control of gene expression: emerging
mechanisms and disruption in disease. Am J Hum Genet 2005;76:8–32.
11. Benito-Sanz S, Thomas NS, Huber C, Gorbenko del Blanco D, Aza-Carmona M,
Crolla JA, Maloney V, Rappold G, Argente J, Campos-Barros A, Cormier-DaireV ,
Heath KE. A novel class of Pseudoautosomal region 1 deletions downstream of SHOX
is associated with Leri-Weill dyschondrosteosis. Am J Hum Genet 2005;77:533–44.
12. Huber C, Rosilio M, Munnich A, Cormier-Daire V, French SHOX GeNeSIS Module.
High incidence of SHOX anomalies in individuals with short stature. J Med Genet
2006;43:735–9.
13. Fukami M, Kato F, Tajima T, Yokoya S, Ogata T. Transactivation function of an
approximately 800-bp evolutionarily conserved sequence at the SHOX 39 region:
implication for the downstream enhancer. Am J Hum Genet 2006;78:167–70.
14. Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, Ross JL,
Niesler B. Genotypes and phenotypes in children with short stature: clinical indicators
of SHOX haploinsufficiency. J Med Genet 2007;44:306–13.
15. Sabherwal N, Bangs F, Ro ¨th R, Weiss B, Jantz K, Tiecke E, Hinkel GK, Spaich C,
Hauffa BP, van der Kamp H, Kapeller J, Tickle C, Rappold G. Long-range conserved
non-coding SHOX sequences regulate expression in developing chicken limb and are
associated with short stature phenotypes in human patients. Hum Mol Genet
2007;16:210–22.
16. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative
quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe
amplification. Nucleic Acids Res 2002;30:e57.
17. Blaschke RJ, Rappold G. The pseudoautosomal regions, SHOX and disease. Curr
Opin Genet Dev 2006;16:233–9.
18. Ross JL, Scott C Jr, Marttila P, Kowal K, Nass A, Papenhausen P, Abboudi J,
Osterman L, Kushner H, Carter P, Ezaki M, Elder F, Wei F, Chen H, Zinn AR.
Phenotypes Associated with SHOX Deficiency. J Clin Endocrinol Metab
2001;86:5674–80.
19. Flanagan SF, Munns CF, Hayes M, Williams B, Berry M, Vickers D, Rao E, Rappold
GA, Batch JA, Hyland VJ, Glass IA. Prevalence of mutations in the short stature
homeobox containing gene (SHOX) in Madelung deformity of childhood. J Med Genet
2002;39:758–63.
20. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J,
Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB,
Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC,
Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW,
Strausberg RL, Venter JC. The diploid genome sequence of an individual human. PLoS
Biol 2007;5:e254.
21. Spitz F, Gonzalez F, Duboule D. A global control region defines a
chromosomal regulatory landscape containing the HoxD cluster. Cell
2003;113:405–17.
22. Bagheri-Fam S, Barrionuevo F, Dohrmann U, Gu ¨nther T, Schu ¨le R, Kemler R, Mallo
M, Kanzler B, Scherer G. Long-range upstream and downstream enhancers control
distinct subsets of the complex spatiotemporal Sox9 expression pattern. Dev Biol
2006;291:382–97.
23. Velagelati GV, Bien-Willner GA, Northup JK, Lockhart LH, Hawkins JC, Jalal SM,
Withers M, Lupski JR, Stankiewicz P. Position effects due to chromosome
breakpoints that map approximately 900 kb upstream and approximately 1.3 Mb
downstream of SOX9 in two patients with campomelic dysplasia. Am J Hum Genet
2005;76:652–62.
24. Benko S, Fantes JA, Amiel J, Kleinjan DJ, Thomas S, Ramsay J, Jamshidi N, Essafi
A, Heaney S, Gordon CT, McBride D, Golzio C, Fisher M, Perry P, Abadie V, AyusoC ,
Holder-Espinasse M, Kilpatrick N, Lees MM, Picard A, Temple IK, Thomas P, Vazquez
MP, Vekemans M, Crollius HR, Hastie ND, Munnich A, Etchevers HC, Pelet A, Farlie
PG, Fitzpatrick DR, Lyonnet S. Highly conserved non-coding elements on either side of
SOX9 associated with Pierre Robin sequence. Nat Genet 2009;41:359–64.
25. Ballabio A, Bardoni B, Carrozzo R, Andria G, Bick D, Campbell L, Hamel B, Ferguson-
Smith MA, Gimelli G, Fraccaro M, Maraschio P, Zuffardi O, Guioli S, CamerinoG .
Contiguous gene syndromes due to deletions in the distal short arm of the human X
chromosome. Proc Natl Acad Sci U S A 1989;86:10001–5.
Original article
J Med Genet 2009;46:834–839. doi:10.1136/jmg.2009.067785 839